Skip to main navigation INVESTOR RELATIONS Transforming community-based healthcare Through a next generation POC diagnostic Platform Corporate Profile We are a next-generation point of care diagnostic company addressing the current limitations of legacy systems by bringing lab-comparable performance to the point of care in minutes, on a single Instrument with a low cost of ownership. We are focused on transforming community-based healthcare by providing critical diagnostic information to healthcare providers at the point of need, thereby enabling more informed medical decisions to improve health outcomes while lowering costs. We have developed and launched the LumiraDx Platform, which is an integrated system comprised of a small, versatile Instrument, low-cost microfluidic Test Strips, and seamless, secure digital connectivity. With our Platform, our goal is to address the key challenges faced by healthcare providers in providing efficient and cost-effective patient care in a community setting. Stock Information NASDAQ GS: LMDX $9.59 +0.075 (+0.79%) Data Provided by Refinitiv. Minimum 15 minutes delayed. Press Releases 01 Dec '21 FDA Reissues LumiraDx Fast Lab Solutions' EUA for SARS CoV-2 RNA STAR Complete Molecular Reagents to Allow High Throughput and Asymptomatic Testing Solutions LONDON , Dec. 1, 2021 /PRNewswire/ -- LumiraDx (Nasdaq: LMDX) announced today that the intended use for its Food and Drug Administration (FDA) Emergency Use Authorization (EUA) SARS-CoV-2 RNA STAR Complete, a rapid, nucleic acid amplification technology for high sensitivity, high throughput 10 Nov '21 LumiraDx Reports Third Quarter 2021 Financial Results Strong Revenue Growth and Strategic Progress on Platform, Products and Pipeline LONDON , Nov. 10, 2021 /PRNewswire/ -- LumiraDx (Nasdaq:LMDX), a next-generation point of care (POC) diagnostics company, today announced financial results for the quarter ended September 30, 2021 . 02 Nov '21 LumiraDx to Announce Third Quarter 2021 Financial Results and Host Quarterly Conference Call on November 10 LONDON , Nov. 2, 2021 /PRNewswire/ -- LumiraDx (Nasdaq:LMDX), a next-generation point of care (POC) diagnostics company, announced it will release its third quarter 2021 financial results on Wednesday, November 10, 2021 . On the day of the release, LumiraDx will host a conference call and webcast 01 Nov '21 LumiraDx Announces the Intended Use for its FDA EUA Authorized High Sensitivity COVID-19 Antigen Test has been Expanded to Include Testing of Asymptomatic Individuals - Microfluidic immunofluorescence assay authorized for screening asymptomatic individuals using a single test with results available in 12 minutes - The test performance for viral antigen detection in asymptomatic individuals was 82.1% positive agreement and 100% negative agreement compared to VIEW MORE NEWS Recent Events November 10, 2021 at 8:00 AM EST LumiraDx Third Quarter 2021 Financial Results Conference Call VIEW MORE EVENTS Featured Reports More information is coming soon. Featured Pages STOCK INFORMATION CONTACT IR SEC FILINGS INVESTOR FAQ Investor Tools PRINT PAGE EMAIL ALERTS RSS FEEDS REQUEST EMAIL ALERTS © 2021 LumiraDx. All rights reserved.